{
  "name": "Oxcarbazepine",
  "genericName": "oxcarbazepine",
  "brandNames": ["Trileptal", "Oxtellar XR"],
  "tags": ["Mood Stabilizer", "Anticonvulsant"],
  "dosing": {
    "adult_acute": "300 mg BID, increase by 300-600 mg/day every 3-7 days",
    "adult_maintenance": "900-2400 mg/day divided BID",
    "notes": "Keto-analogue of carbamazepine; better tolerated; less drug interactions; no autoinduction; no need for level monitoring",
    "canadian_clinical": {
      "starting_dose": "300 mg BID",
      "titration_schedule": "Increase by 300-600 mg/day every 3-7 days",
      "max_dose_evidence": "2400 mg/day",
      "max_dose_practice": "1800-2400 mg/day divided BID",
      "inpatient_strategy": "Start 300-600 mg BID; increase by 300-600 mg every 3-7 days to 1200-1800 mg",
      "outpatient_strategy": "Start 300 mg BID; increase weekly; generally better tolerated than carbamazepine"
    }
  },
  "warnings": [
    "Black box warning: Serious dermatologic reactions (SJS, TEN) - cross-reactivity with carbamazepine in ~25-30%",
    "HLA-B*1502 screening recommended in Asian patients (same as carbamazepine)",
    "Hyponatremia (more common than carbamazepine) - monitor sodium, especially in elderly",
    "No autoinduction (unlike carbamazepine)",
    "Fewer drug interactions than carbamazepine but still moderate CYP3A4 inducer",
    "May reduce efficacy of oral contraceptives",
    "No need for routine blood level monitoring"
  ],
  "cautions": {
    "renal": "CrCl <30: Start at 50% dose and titrate slowly; monitor for fluid/electrolyte disturbances",
    "hepatic": "Use with caution; not recommended in severe impairment",
    "pregnancy": "Pregnancy Category C; limited data; likely similar risks to carbamazepine"
  },
  "citations": ["CANMAT Bipolar Guidelines", "Trileptal FDA Label", "APA Guidelines"]
}
